Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference CallBusiness Wire • 02/09/23
Charles River Laboratories (CRL) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 02/08/23
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing AllianceBusiness Wire • 01/18/23
Should You Buy Charles River Laboratories (CRL) After Golden Cross?Zacks Investment Research • 01/12/23
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA ProgramsBusiness Wire • 01/12/23
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin DetectionBusiness Wire • 12/01/22
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research ProgramBusiness Wire • 11/28/22
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022Business Wire • 11/10/22
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO ClientsBusiness Wire • 11/07/22
Charles River Laboratories International, Inc. (CRL) Q3 2022 Earnings Call TranscriptSeeking Alpha • 11/02/22
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy ResearchBusiness Wire • 10/19/22